Phase II clinical study of BC-3781, a pleuromutilin antibiotic, in treatment of patients with acute bacterial skin and skin structure infections

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 5, 2013, Pages 2087-2094

  Prince, W T ^a   Ivezic Schoenfeld, Z ^a   Lell, C ^a   Tack, K J ^b   Novak, R ^a   Obermayr, F ^a   Talbot, G H ^a,c  

^a Nabriva Therapeutics Inc   (Austria)

^b Independent Consultant   (United States)

^c Talbot Advisors LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BC 3781; PLEUROMUTILIN; UNCLASSIFIED DRUG; VANCOMYCIN;

ABDOMINAL PAIN; ABSCESS; ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTION; ADULT; ADVERSE OUTCOME; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACTERIAL SKIN DISEASE; BURN INFECTION; CELLULITIS; CONSTIPATION; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DIARRHEA; DOUBLE BLIND PROCEDURE; ERYSIPELAS; FEMALE; HEADACHE; HUMAN; HYPERHIDROSIS; INCIDENCE; INJECTION SITE PAIN; INJECTION SITE PHLEBITIS; INJECTION SITE REACTION; INSOMNIA; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MODIFIED INTENT TO TREAT; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TEST OF CURE; TINNITUS; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING; VULVOVAGINA MYCOTIC INFECTION; VULVOVAGINITIS; WOUND INFECTION;

ACUTE DISEASE; ADULT; ANTI-BACTERIAL AGENTS; DITERPENES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MIDDLE AGED; SKIN; SKIN DISEASES, BACTERIAL; STAPHYLOCOCCAL INFECTIONS; TREATMENT OUTCOME; VANCOMYCIN;

EID: 84876239981     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02106-12     Document Type: Article

References (22)

1. Eron LJ, Lipsky BA, Low DE, Nathwani D, Tice AD, Volturo GA. 2003. Managing skin and soft tissue infections: expert panel recommendations on key decision points. J. Antimicrob. Chemother. 52(Suppl 1):i3-i17.
2. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, Dowell SF, File TM, Jr, Musher DM, Niederman MS, Torres A, Whitney CG. 2007. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community- acquired pneumonia in adults. Clin. Infect. Dis. 44(Suppl 2):S27-S72.
3. Stevens DL, Bisno AL, Chambers HF, Everett ED, Dellinger P, Goldstein EJ, Gorbach SL, Hirschmann JV, Kaplan EL, Montoya JG, Wade JC. 2005. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin. Infect. Dis. 41:1373-1406.
4. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Jr, Gilbert D, Rice L, Scheld BM, Spellberg B, Bartlett J. 2009. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin. Infect. Dis. 48:1-12.
5. Cosgrove SE, Carroll KC, Perl TM. 2004. Staphylococcus aureus with reduced susceptibility to vancomycin. Clin. Infect. Dis. 39:539-545.
6. Hawser S, Lociuro S, Islam K. 2006. In vitro activity of iclaprim against Staphylococcus aureus, group A and group B streptococci, abstr CPLA 34. Abstr. Third Int. Symp. Resistant Gram-Positive Infect.
7. Novak R, Shlaes DM. 2010. The pleuromutilin antibiotics: a new class for human use. Curr. Opin. Investig. Drugs 11:182-191.
8. Sader HS, Biedenbach DJ, Paukner S, Ivezic-Schoenfeld Z, Jones RN. 2012. Antimicrobial activity of the investigational pleuromutilin compound BC-3781 tested against Gram-positive organisms commonly associated with acute bacterial skin and skin structure infections. Antimicrob. Agents Chemother. 56:1619-1623.
9. Sader HS, Farrell DJ, Biedenbach DJ, Jones RN. 2011. Antimicrobial activity of BC-3781, an investigational pleuromutilin, tested against organisms isolated from patients with community-acquired respiratory tract infections (CARTI) and acute bacterial skin and skin structure infections (ABSSSI), abstr C2-1798. Abstr. 51st Intersci. Conf. Antimicrob. Agents Chemother., Chicago, IL. American Society for Microbiology, Washington, DC.
10. Sader HS, Paukner S, Ivezic-Schoenfeld Z, Biedenbach DJ, Schmitz J, Jones F-RN. 2012. Antimicrobial activity of the novel pleuromutilin antibiotic BC-3781 against organisms responsible for community-acquired respiratory tract infections (CARTI). J. Antimicrob. Chemother. 67: 1170-1175.
11. Prince WT, Wicha WW, Strickman DB, Moschetti V, Obermayr F, Novak R. 2010. Safety, tolerance and pharmacokinetics of single and repeat doses of BC-3781, a novel antimicrobial, abstr P906. Abstr. 20th Eur. Congr. Clin. Microbiol. Infect. Dis.
12. Wicha WW, Lell C, Logan Prince DK WT. 2010. An age gender study investigating the safety, tolerance and pharmacokinetics of BC-3781, abstr A1-01. Abstr. 50th Intersci. Conf. Antimicrob. Agents Chemother., San Francisco, CA. American Society for Microbiology, Washington, DC.
13. Prince WT, Obermayr F, Ivezic-Schoenfeld Z, Lell C, Wicha WW, Strickmann DB, Tack KJ, Novak R. 2011. A phase 2 study comparing the safety and efficacy of two doses of BC-3781 versus vancomycin in acute bacterial skin and skin structure infections (ABSSSI), abstr. L-966. Abstr. 51st Intersci. Conf. Antimicrob. Agents Chemother., Chicago, IL. American Society for Microbiology, Washington, DC.
14. Prince W, Obermayr F, Lell C, Das A, Talbot GH. 2012. Assessment of two early-response outcome measures in a phase II clinical trial of the pleuromutilin BC-3781 in acute bacterial skin and skin structure infections, abstr. P693. Abstr. 22nd Eur. Congr. Clin. Microbiol. Infect. Dis.
15. Corey GR, Wilcox M, Talbot GH, Friedland HD, Baculik T, Witherell GW, Critchley I, Das AF, Thye D. 2010. Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection. Clin. Infect. Dis. 51:641-650.
16. Bhavnani SM, Hammel JP, Rubino CM, Bulik CC, Reynolds DK, Ivezic-Schoenfeld Z, Wicha WW, Novak R, Prince WT, Ambrose PG. 2011. Pharmacokinetic-pharmacodynamic analysis for efficacy of BC- 3781 using new clinical trial endpoints in patients with acute bacterial skin and skin structure infection, abstr A2-042. Abstr. 51th Intersci. Conf. Antimicrob. Agents Chemother., Chicago, IL. American Society for Microbiology, Washington, DC.
17. Stryjewski ME, Graham DR, Wilson SE, O'Riordan W, Young D, Lentnek A, Ross DP, Fowler VG, Hopkins A, Friedland HD, Barriere SL, Kitt MM, Corey GR. 2008. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms. Clin. Infect. Dis. 46:1683-1693.
18. Noel GJ, Strauss RS, Amsler K, Heep M, Pypstra R, Solomkin JS. 2008. Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteria. Antimicrob. Agents Chemother. 52:37-44.
19. Lipsky BA, Itani KM, Weigelt JA, Joseph W, Paap CM, Reisman A, Myers DE, Huang DB. 2011. The role of diabetes mellitus in the treatment of skin and skin structure infections caused by methicillin-resistant Staphylococcus aureus: results from three randomized controlled trials. Int. J. Infect. Dis. 15:3140-3146.
20. Food and Drug Administration, Center for Drug Evaluation. August2010. Guidance for industry: acute bacterial skin and skin structure infections: developing drugs for treatment. Food and Drug Administration, Rockville, MD. http://www.fda.gov/downloads/Drugs/Guidance ComplianceRegulatoryInformation/ Guidances/ucm071185.pdf.
21. Talbot GH, Powers JH, Fleming TR, Siuciak JA, Bradley J, Boucher H on behalf of the Project Team CABP-ABSSSI. 2012. Progress on developing endpoints for registrational clinical trials of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections: update from the Biomarkers Consortium of the Foundation for the National Institutes of Health. Clin. Infect. Dis. 55:1114-1121.
22. Rubino CM, Xue B, Bhavnani SM, Prince WT, Ivezic-Schoenfeld Z, Wicha WW, Ambrose PG. 2011. Population pharmacokinetic analyses for BC-3781 using phase 2 data, abstr. A2-2. Abstr. 51st Intersci. Conf. Antimicrob. Agents Chemother., Chicago, IL. American Society for Microbiology, Washington, DC.